A Look At Takeda Pharmaceutical (TSE:4502) Valuation As New CEO And Transformation Plan Take Shape

Takeda Pharmaceutical (TSE:4502) is in the spotlight after appointing Julie Kim as CEO and outlining a transformation plan focused on cost savings, margin improvements, and upcoming product launches that could reshape how investors view the stock.

See our latest analysis for Takeda Pharmaceutical.

At a share price of ¥4,926, Takeda’s recent 30 day share price return is down 6% and the 90 day share price return is down 13%, yet the 1 year total shareholder return of 19% signals longer term holders have still seen solid gains as leadership changes, product launch expectations, and the withdrawal and refiling of shelf registrations shape how investors assess both upside and risk.

If this reshaping of Takeda’s story has you thinking about where else the market might be re-rating opportunities, it could be a useful time to scan 7 healthcare AI stocks

With the share price under pressure in recent months but longer term returns still positive, investors are left with a simple question: is Takeda’s transformation story still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 34.7% Undervalued

Against Takeda’s last close at ¥4,926, the most followed narrative pins fair value at ¥7,544. This frames the current transformation plan as central to the valuation debate.

The planned launches of oveporexton and rusfertide over the next 12 months, together with zasocitinib in psoriasis around 2027, position Takeda to add new high value products that management believes can more than offset expected ENTYVIO biosimilar pressure in the early 2030s. This is aimed squarely at supporting revenue and earnings durability.

Read the complete narrative.

Want to see what sits underneath that confidence in new launches? The narrative leans heavily on step ups in revenue, margins and earnings that assume a very different Takeda by the end of the decade.

Result: Fair Value of ¥7,544 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this upbeat story can quickly be tested if key pipeline drugs stumble at regulators or if ENTYVIO and VYVANSE face sharper than expected pricing and volume pressure.

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Another View: Valuation Tension From P/E

While the bullish narrative leans on future earnings power, today Takeda trades on a P/E of 40.6x, compared with a fair ratio of 34.8x, the JP Pharmaceuticals industry at 16.1x, and peers at 18.3x. That premium can signal confidence, but also raises the question of how much good news is already reflected in the price.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the story pulling in different directions, it helps to move quickly, look past the headlines, and weigh the trade off between concern and optimism using our breakdown of 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If Takeda has sharpened your focus on where risk and reward line up best, do not stop here. Broaden your watchlist before the market moves on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com